Compare Arqit Quantum Inc (ARQQ) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arqit Quantum Inc vs Charles River Laboratories Intl. Inc — how do they compare? Arqit Quantum Inc trades at $18.95 (market cap $332.04M), while Charles River Laboratories Intl. Inc trades at $233.41 (market cap $11.24B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 33.9× Arqit Quantum Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | CRL | |
|---|---|---|
Market Cap | $332.04M | $11.24B |
Sector | Technology | Health |
52-Week High | $58.27 | $233.60 |
52-Week Low | $11.78 | $145.57 |
Enterprise Value | $305.35M | $14.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
Charles River Laboratories (CRL) trades at $233.41, down slightly by 0.08% today, with a bullish technical signal supported by moving averages. The company shows strong operational cash flow of $737.65M for 2025 but faces profitability challenges with negative net income margin of -4.59% and ROE of -6.02%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly positive with 72% buy ratings.
CRL presents a mixed investment case: strong cash generation and strategic collaborations like the Lilly TuneLab partnership provide growth catalysts, but negative profitability metrics and high valuation ratios (P/E 684.85) pose risks. The stock's outlook depends on margin improvement and successful execution of recent business initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
